Loading
Histone Deacetylase Inhibitors Research / Epigenetics and DNA Methylation / Cancer Related Gene Regulation · Journal article
Scientific Reports · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic in vitro study showing that 5-Azacytidine, a DNMT1 inhibitor, reduces invasion and migration in two of three docetaxel-resistant prostate cancer cell lines through modulation of EMT markers, particularly upregulation of CDH1 and downregulation of SNAI2 and VIM. The work provides exploratory evidence for epigenetic regulation of therapy resistance but lacks animal models, pharmacokinetic data, and clinical validation required to assess therapeutic potential.
In vitro cell line study (uncontrolled). Three parental prostate cancer cell lines (22Rv1, PC3, DU145) and their docetaxel-resistant derivatives generated in house.. Intervention: 5-Azacytidine (5-AZA) at doses of 0.5–16 µM for 72 hours. Compared with: Untreated parental and docetaxel-resistant cell lines (implicit control).
5-AZA reduced invasion in DU145-DR cells at 1 µM (p<0.05) and 2 µM (p<0.0001) and in PC3-DR cells at 1 µM (p<0.0001) and 2 µM (p<0.01) CDH1 was upregulated in DU145-DR (p<0.05) and PC3-DR (p<0.01) cells after 5-AZA treatment SNAI2 (p<0.05) and VIM (p<0.01) were significantly downregulated in DU145-DR cells only
No in vivo validation, animal models, or pharmacokinetic studies reported.
This exploratory work suggests a potential mechanism by which DNMT1 inhibition may reduce metastatic potential in chemotherapy-resistant prostate cancer, but the findings are preliminary and confined to cell culture. Clinical researchers should view this as hypothesis-generating work that would require in vivo validation and eventual human trials before considering therapeutic application in mCRPC.
In vitro mechanistic study in cancer cell lines demonstrating that DNMT1 inhibition modulates EMT markers and reduces invasiveness in docetaxel-resistant prostate cancer, but lacks in vivo validation, clinical endpoints, or human data.
As stated by the source record.
Quoted from the source exactly as published.
This exploratory work suggests a potential mechanism by which DNMT1 inhibition may reduce metastatic potential in chemotherapy-resistant prostate cancer, but the findings are preliminary and confined to cell culture. Clinical researchers should view this as hypothesis-generating work that would require in vivo validation and eventual human trials before considering therapeutic application in mCRPC.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract. Background: Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis and high mortality, largely due to the emergence of androgen and chemotherapy resistance. Resistance to docetaxel occurs in nearly 50% of patients and remains a major clinical challenge. DNA methylation is known to contribute to therapy resistance through gene silencing and reprogramming of cellular pathways. This study investigated whether global DNA hypomethylation achieved through DNMT1 inhibition could reduce cell invasion and motility in docetaxel-resistant (DR) prostate cancer (PCa) cells. Results: Parental and DR PCa cell lines (22Rv1, PC3, and DU145) were treated with 5-Azacytidine (5-AZA: 0.5–16 µM) for 72 hrs. Treatment with 5-AZA reduced cell viability in a dose-dependent manner in all cell models except DU-145DR cells. DNMT1 inhibition was confirmed in all cell lines, while re-expression of GSTP1, indicating successful DNA hypomethylation, was observed in DU145-DR and PC3/PC3-DR cells. No changes were observed in androgen receptor (AR), AR variant 7 (AR-V7), or MDR1 protein expression. Invasion capacity was significantly reduced in DU145-DR (1 µM: p<0.05; 2 µM: p<0.0001) and PC3-DR (1 µM: p<0.0001; 2 µM: p<0.01) cells. Migration capacity was also reduced in DU145-DR and PC3-DR cells following 5-AZA treatment. 5-AZA induced upregulation of CDH1 (DU145-DR: p<0.05; PC3-DR: p<0.01) and downregulation of TJP1 (DU145-DR: p<0.01; PC3-DR: p<0.01) compared to parental cells. Additionally, SNAI2 (p<0.05) and VIM (p<0.01) were significantly downregulated only in DU145-DR cells, suggesting a cell line–specific modulation of epithelial–mesenchymal transition (EMT) markers. Conclusions: These findings demonstrate that DNMT1 inhibition modulates EMT-related pathways, leading to reduced invasion and migrations in docetaxel-resistant PCa cells. The effect of 5-AZA appears to be mediated by upregulation of CDH1 and suppression of SNAI2 and VIM, highlighting the role of DNa methylation as a regulator of metastatic potential. This study provides mechanistic insight into the epigenetic regulation of therapy resistance and supports the potential of DNMT1 inhibition as a strategy to mitigate aggressive behavior in docetaxel-resistant mCRPC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.